 Elizabeth Redente
Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Fibrosis | 10 | 2021 | 321 | 2.520 |
Why?
| | Idiopathic Pulmonary Fibrosis | 9 | 2021 | 500 | 2.330 |
Why?
| | Lung | 19 | 2020 | 3497 | 1.480 |
Why?
| | Bleomycin | 13 | 2021 | 227 | 1.370 |
Why?
| | Fibroblasts | 10 | 2021 | 827 | 1.270 |
Why?
| | Macrophages, Alveolar | 5 | 2016 | 341 | 1.240 |
Why?
| | fas Receptor | 4 | 2020 | 89 | 0.940 |
Why?
| | Signal Transduction | 11 | 2021 | 4439 | 0.920 |
Why?
| | Alveolar Epithelial Cells | 6 | 2019 | 93 | 0.870 |
Why?
| | Collagen | 5 | 2019 | 411 | 0.760 |
Why?
| | Cytoskeletal Proteins | 1 | 2021 | 133 | 0.710 |
Why?
| | Lung Injury | 4 | 2019 | 192 | 0.710 |
Why?
| | Arthritis, Experimental | 3 | 2018 | 123 | 0.710 |
Why?
| | Transforming Growth Factor beta | 6 | 2020 | 435 | 0.700 |
Why?
| | Monocytes | 4 | 2018 | 499 | 0.650 |
Why?
| | Indoles | 2 | 2019 | 296 | 0.650 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2020 | 122 | 0.640 |
Why?
| | Respiratory Mucosa | 2 | 2019 | 251 | 0.610 |
Why?
| | Mice | 29 | 2021 | 14679 | 0.580 |
Why?
| | Cell Separation | 2 | 2019 | 288 | 0.580 |
Why?
| | Epithelial Cells | 3 | 2021 | 939 | 0.560 |
Why?
| | Animals | 37 | 2021 | 31162 | 0.520 |
Why?
| | Wnt Signaling Pathway | 1 | 2017 | 145 | 0.490 |
Why?
| | Serum Response Factor | 1 | 2015 | 28 | 0.480 |
Why?
| | Macrophages | 4 | 2018 | 1233 | 0.460 |
Why?
| | Mice, Inbred C57BL | 12 | 2021 | 4617 | 0.460 |
Why?
| | Flow Cytometry | 4 | 2020 | 1065 | 0.460 |
Why?
| | Mesoderm | 1 | 2015 | 130 | 0.450 |
Why?
| | Apoptosis | 5 | 2019 | 2288 | 0.430 |
Why?
| | Lung Neoplasms | 6 | 2018 | 2148 | 0.420 |
Why?
| | Cell Polarity | 2 | 2010 | 127 | 0.400 |
Why?
| | Trans-Activators | 1 | 2015 | 356 | 0.400 |
Why?
| | Interferon-gamma | 3 | 2010 | 710 | 0.400 |
Why?
| | Mice, Knockout | 10 | 2020 | 2523 | 0.390 |
Why?
| | Disease Progression | 3 | 2021 | 2364 | 0.350 |
Why?
| | Disease Models, Animal | 9 | 2020 | 3470 | 0.340 |
Why?
| | X-Ray Microtomography | 2 | 2021 | 73 | 0.330 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1106 | 0.320 |
Why?
| | Bone Marrow Cells | 1 | 2010 | 262 | 0.320 |
Why?
| | Cells, Cultured | 9 | 2020 | 3802 | 0.310 |
Why?
| | Adenoma | 2 | 2007 | 187 | 0.300 |
Why?
| | Receptors, Cell Surface | 1 | 2009 | 347 | 0.290 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 2 | 2020 | 23 | 0.280 |
Why?
| | Pneumonia | 3 | 2016 | 561 | 0.280 |
Why?
| | Urethane | 1 | 2007 | 40 | 0.270 |
Why?
| | Carcinogens | 1 | 2007 | 101 | 0.260 |
Why?
| | Melanoma, Experimental | 2 | 2018 | 89 | 0.250 |
Why?
| | Bone Marrow | 1 | 2007 | 242 | 0.250 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2007 | 305 | 0.230 |
Why?
| | Lung Compliance | 3 | 2014 | 46 | 0.230 |
Why?
| | Adenocarcinoma | 2 | 2009 | 787 | 0.230 |
Why?
| | Fluorescent Antibody Technique | 2 | 2018 | 383 | 0.220 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1029 | 0.210 |
Why?
| | Fibroblast Growth Factor 10 | 2 | 2019 | 24 | 0.200 |
Why?
| | Single-Cell Analysis | 2 | 2020 | 185 | 0.190 |
Why?
| | Acute Lung Injury | 2 | 2017 | 266 | 0.190 |
Why?
| | Male | 19 | 2021 | 55112 | 0.190 |
Why?
| | Proline | 1 | 2021 | 72 | 0.180 |
Why?
| | Lung Diseases, Interstitial | 2 | 2019 | 494 | 0.180 |
Why?
| | Regeneration | 2 | 2019 | 158 | 0.180 |
Why?
| | Lung Diseases | 2 | 2019 | 688 | 0.170 |
Why?
| | Multimodal Imaging | 1 | 2020 | 89 | 0.170 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2011 | 578 | 0.170 |
Why?
| | Humans | 19 | 2021 | 113531 | 0.170 |
Why?
| | Neoplasms, Experimental | 1 | 2020 | 149 | 0.170 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2019 | 21 | 0.160 |
Why?
| | Interleukin-4 | 2 | 2010 | 202 | 0.160 |
Why?
| | Mice, Transgenic | 4 | 2019 | 1925 | 0.160 |
Why?
| | Extracellular Matrix | 2 | 2019 | 433 | 0.160 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 13 | 1 | 2018 | 7 | 0.160 |
Why?
| | Gene Deletion | 2 | 2018 | 351 | 0.160 |
Why?
| | Pulmonary Surfactant-Associated Proteins | 1 | 2018 | 10 | 0.150 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2018 | 20 | 0.150 |
Why?
| | CD11 Antigens | 1 | 2018 | 27 | 0.150 |
Why?
| | Imaging, Three-Dimensional | 1 | 2021 | 509 | 0.140 |
Why?
| | Adaptive Immunity | 1 | 2018 | 153 | 0.140 |
Why?
| | Macrophage Activation | 2 | 2009 | 162 | 0.140 |
Why?
| | Immunoglobulin M | 1 | 2018 | 244 | 0.140 |
Why?
| | Myofibroblasts | 1 | 2018 | 115 | 0.140 |
Why?
| | Homeostasis | 1 | 2020 | 561 | 0.140 |
Why?
| | Antigens, Neoplasm | 1 | 2018 | 222 | 0.140 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2018 | 344 | 0.130 |
Why?
| | Neoplasms | 1 | 2010 | 2082 | 0.130 |
Why?
| | Phospholipases A2 | 1 | 2016 | 72 | 0.130 |
Why?
| | Lung Diseases, Fungal | 1 | 2016 | 13 | 0.130 |
Why?
| | Candidiasis | 1 | 2016 | 51 | 0.130 |
Why?
| | Candida albicans | 1 | 2016 | 49 | 0.130 |
Why?
| | CD11b Antigen | 1 | 2016 | 56 | 0.130 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2016 | 53 | 0.130 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1510 | 0.130 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2018 | 686 | 0.130 |
Why?
| | Phagocytes | 1 | 2016 | 85 | 0.130 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2020 | 636 | 0.130 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2017 | 248 | 0.120 |
Why?
| | Dendritic Cells | 1 | 2018 | 432 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2021 | 1008 | 0.120 |
Why?
| | Stem Cells | 1 | 2019 | 538 | 0.120 |
Why?
| | Mice, Inbred BALB C | 3 | 2016 | 1136 | 0.120 |
Why?
| | Pulmonary Alveoli | 1 | 2017 | 369 | 0.120 |
Why?
| | Receptor, Macrophage Colony-Stimulating Factor | 1 | 2014 | 6 | 0.110 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2014 | 15 | 0.110 |
Why?
| | Hydroxyproline | 1 | 2014 | 21 | 0.110 |
Why?
| | Female | 13 | 2019 | 59115 | 0.110 |
Why?
| | Arthritis, Rheumatoid | 2 | 2013 | 996 | 0.110 |
Why?
| | Antigens, CD | 1 | 2016 | 437 | 0.110 |
Why?
| | Remission Induction | 1 | 2014 | 233 | 0.110 |
Why?
| | Wound Healing | 2 | 2017 | 253 | 0.110 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2013 | 63 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2018 | 960 | 0.100 |
Why?
| | Mice, Inbred Strains | 2 | 2010 | 394 | 0.100 |
Why?
| | Delayed-Action Preparations | 1 | 2012 | 158 | 0.100 |
Why?
| | Leukocytes | 1 | 2013 | 268 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 783 | 0.100 |
Why?
| | Pyridones | 1 | 2012 | 122 | 0.100 |
Why?
| | Neutrophils | 1 | 2016 | 1072 | 0.090 |
Why?
| | Chemokine CXCL1 | 1 | 2011 | 67 | 0.090 |
Why?
| | Colonic Neoplasms | 1 | 2013 | 210 | 0.090 |
Why?
| | Up-Regulation | 2 | 2011 | 794 | 0.090 |
Why?
| | Trauma Severity Indices | 1 | 2011 | 108 | 0.090 |
Why?
| | Schistosoma mansoni | 1 | 2010 | 33 | 0.090 |
Why?
| | Sex Characteristics | 2 | 2013 | 633 | 0.090 |
Why?
| | Recovery of Function | 1 | 2014 | 567 | 0.090 |
Why?
| | Butylated Hydroxytoluene | 1 | 2010 | 31 | 0.090 |
Why?
| | Schistosomiasis | 1 | 2010 | 37 | 0.080 |
Why?
| | Granuloma | 1 | 2010 | 82 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 297 | 0.080 |
Why?
| | Testosterone | 1 | 2013 | 341 | 0.080 |
Why?
| | Interleukin-13 | 1 | 2010 | 121 | 0.080 |
Why?
| | Antigens | 1 | 2011 | 316 | 0.080 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 191 | 0.080 |
Why?
| | Intubation, Intratracheal | 1 | 2011 | 216 | 0.080 |
Why?
| | Nanoparticles | 1 | 2012 | 308 | 0.080 |
Why?
| | Immunity, Innate | 2 | 2016 | 716 | 0.080 |
Why?
| | Hepatocyte Growth Factor | 2 | 2019 | 32 | 0.080 |
Why?
| | Sex Factors | 2 | 2011 | 1705 | 0.080 |
Why?
| | Lymph Nodes | 1 | 2011 | 412 | 0.080 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 779 | 0.080 |
Why?
| | Biomarkers | 1 | 2018 | 3389 | 0.070 |
Why?
| | Autoimmunity | 1 | 2013 | 813 | 0.070 |
Why?
| | Survival Rate | 1 | 2011 | 1634 | 0.070 |
Why?
| | Tuberculosis | 1 | 2010 | 239 | 0.070 |
Why?
| | Angiogenesis Inhibitors | 1 | 2009 | 212 | 0.070 |
Why?
| | Neovascularization, Pathologic | 1 | 2009 | 280 | 0.070 |
Why?
| | Cell Line | 3 | 2019 | 2581 | 0.070 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2007 | 156 | 0.070 |
Why?
| | Mast Cells | 1 | 2007 | 117 | 0.060 |
Why?
| | Quinazolines | 1 | 2007 | 239 | 0.060 |
Why?
| | Rats | 3 | 2019 | 4829 | 0.060 |
Why?
| | Cytokines | 4 | 2016 | 1795 | 0.060 |
Why?
| | ErbB Receptors | 1 | 2007 | 553 | 0.060 |
Why?
| | Lipopolysaccharides | 2 | 2019 | 802 | 0.060 |
Why?
| | Age Factors | 1 | 2011 | 2875 | 0.060 |
Why?
| | Chronic Disease | 1 | 2010 | 1570 | 0.060 |
Why?
| | Time Factors | 1 | 2014 | 6032 | 0.060 |
Why?
| | Wounds and Injuries | 1 | 2010 | 674 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 2077 | 0.050 |
Why?
| | Phosphorylation | 2 | 2020 | 1537 | 0.050 |
Why?
| | Phenotype | 2 | 2019 | 2754 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2019 | 2752 | 0.050 |
Why?
| | Cell Proliferation | 3 | 2017 | 2164 | 0.050 |
Why?
| | Photoacoustic Techniques | 1 | 2020 | 3 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2018 | 2507 | 0.050 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 75 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1604 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2010 | 1733 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2020 | 260 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2018 | 2293 | 0.040 |
Why?
| | Scleroderma, Systemic | 1 | 2019 | 90 | 0.040 |
Why?
| | Fibroblast Growth Factor 7 | 1 | 2018 | 16 | 0.040 |
Why?
| | CD40 Ligand | 1 | 2018 | 37 | 0.040 |
Why?
| | Culture Media, Serum-Free | 1 | 2018 | 42 | 0.040 |
Why?
| | Pulmonary Surfactants | 1 | 2019 | 100 | 0.040 |
Why?
| | Tissue Culture Techniques | 1 | 2018 | 65 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 148 | 0.040 |
Why?
| | Drug Resistance, Microbial | 1 | 2018 | 66 | 0.040 |
Why?
| | Antigen-Presenting Cells | 1 | 2018 | 149 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2019 | 125 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2018 | 180 | 0.040 |
Why?
| | Congresses as Topic | 1 | 2019 | 194 | 0.040 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2018 | 127 | 0.040 |
Why?
| | Lipogenesis | 1 | 2018 | 56 | 0.040 |
Why?
| | Fibrosis | 1 | 2019 | 452 | 0.040 |
Why?
| | Chemokine CXCL12 | 1 | 2017 | 74 | 0.030 |
Why?
| | Receptors, CXCR4 | 1 | 2017 | 78 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2007 | 1872 | 0.030 |
Why?
| | Reference Values | 1 | 2018 | 735 | 0.030 |
Why?
| | Permeability | 1 | 2017 | 144 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2018 | 528 | 0.030 |
Why?
| | Eicosanoids | 1 | 2016 | 52 | 0.030 |
Why?
| | Arachidonic Acid | 1 | 2016 | 110 | 0.030 |
Why?
| | Down-Regulation | 1 | 2018 | 593 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2019 | 442 | 0.030 |
Why?
| | Societies, Medical | 1 | 2019 | 654 | 0.030 |
Why?
| | Organ Specificity | 1 | 2016 | 262 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2018 | 1032 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2017 | 496 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2016 | 331 | 0.030 |
Why?
| | Smad Proteins | 1 | 2014 | 37 | 0.030 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2014 | 51 | 0.030 |
Why?
| | NIH 3T3 Cells | 1 | 2014 | 137 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2016 | 469 | 0.030 |
Why?
| | Genes, Reporter | 1 | 2014 | 248 | 0.030 |
Why?
| | Disease Resistance | 1 | 2013 | 28 | 0.030 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2013 | 42 | 0.030 |
Why?
| | Adenoviridae | 1 | 2014 | 179 | 0.030 |
Why?
| | Polyglactin 910 | 1 | 2012 | 6 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2013 | 227 | 0.030 |
Why?
| | Bronchoalveolar Lavage | 1 | 2012 | 82 | 0.030 |
Why?
| | Tumor Burden | 1 | 2013 | 257 | 0.030 |
Why?
| | Cell Movement | 1 | 2016 | 852 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1378 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 2993 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2269 | 0.020 |
Why?
| | Instillation, Drug | 1 | 2011 | 9 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2011 | 271 | 0.020 |
Why?
| | Fas Ligand Protein | 1 | 2011 | 55 | 0.020 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2013 | 223 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1397 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2011 | 132 | 0.020 |
Why?
| | Smoke | 1 | 2011 | 122 | 0.020 |
Why?
| | Smad3 Protein | 1 | 2010 | 41 | 0.020 |
Why?
| | Tumor Microenvironment | 1 | 2013 | 428 | 0.020 |
Why?
| | Smad2 Protein | 1 | 2010 | 32 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3013 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 595 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2009 | 117 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2010 | 519 | 0.020 |
Why?
| | Immunoblotting | 1 | 2009 | 277 | 0.020 |
Why?
| | Microvessels | 1 | 2009 | 66 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1282 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1140 | 0.020 |
Why?
| | Transcriptome | 1 | 2013 | 719 | 0.020 |
Why?
| | Injections, Intraperitoneal | 1 | 2007 | 97 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1128 | 0.020 |
Why?
| | Erlotinib Hydrochloride | 1 | 2007 | 64 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 6296 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2010 | 1208 | 0.020 |
Why?
| | STAT3 Transcription Factor | 1 | 2009 | 171 | 0.020 |
Why?
| | Aged | 2 | 2018 | 18944 | 0.020 |
Why?
| | Silymarin | 1 | 2009 | 194 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2007 | 227 | 0.020 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2010 | 575 | 0.020 |
Why?
| | Middle Aged | 2 | 2018 | 26552 | 0.020 |
Why?
| | NF-kappa B | 1 | 2009 | 615 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2361 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1589 | 0.010 |
Why?
| | Body Weight | 1 | 2007 | 853 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2007 | 1822 | 0.010 |
Why?
| | United States | 1 | 2019 | 12137 | 0.010 |
Why?
| | Inflammation | 1 | 2010 | 2444 | 0.010 |
Why?
| | Prospective Studies | 1 | 2011 | 6189 | 0.010 |
Why?
| | Mutation | 1 | 2007 | 3313 | 0.010 |
Why?
|
|
Redente's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|